Johnson & Johnson (NYSE:JNJ) and Medtronic (NYSE:MDT) were named in the Boston Consulting Group’s list of the 50 most innovative companies this year at the 20 and 42 spot, respectively. Apple (NSDQ:AAPL) and Google (NSDQ:GOOG) took the top 2 spots on the list. Other notable entries were Gilead at number 8, Bayer‘s (ETR:BAYN) at 11, Biogen (NSDQ:BIIB) at […]
Biogen
Massachusetts Life Sciences Center awards $25 million in tax incentives
The Massachusetts Life Science Center has doled out more than $25 million to 25 life science companies who pledged to create new jobs in its latest round of tax incentives,
BSX launches Promus Element stent in Japan | Regulatory Roundup
DJO Global’s executive vice president resigns | Personnel Moves
Medical device maker DJO Global, Inc. announced that its executive vice president of U.S. commercial operations, Andrew Holman, will leave the company “to pursue other opportunities.”
Newly minted DJO president & CEO Mike Mogul will assume responsibility for the San Diego, Calif.-based company’s U.S. commercial activities.
SyntheMed and Pathfinder become Pathfinder Cell Therapy after merger | Acquisitions Roundup
Closing an agreement that’s been in the works since January, SyntheMed, Inc. (OTC:SYMD), a biomaterials company, changed its name to Pathfinder Cell Therapy, after merging with the biotechnology company.
Richard Franklin, who was President & CEO of Pathfinder, will keep his corner office and Joerg Gruber, a former director of SyntheMed will serve as chairman of the board for the newly created company.
Biogen gets European approval on injectable pen for MS therapy
Biogen Idec (NSDQ:BIIB) announced European approval on an injectable pen that delivers its top-selling multiple sclerosis drug Avonex.
Avonex is used as a treatment for relapsing forms of MS. The drug slows the progression of physical disability and reduces relapses.
Weston, Mass.-based Biogen makes Avonex at a manufacturing facility in North Carolina’s Research Triangle Park.